| Code | CSB-RA015007MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to obinutuzumab, targeting MS4A1 (CD20), a B-cell-specific surface antigen. MS4A1 is a transmembrane phosphoprotein expressed throughout B-cell development from the pre-B stage until plasma cell differentiation. This antigen plays a crucial role in regulating B-cell activation, proliferation, and calcium influx across the cell membrane. MS4A1 is widely recognized as a critical therapeutic target in B-cell malignancies, including chronic lymphocytic leukemia, follicular lymphoma, and non-Hodgkin lymphoma, as well as in autoimmune disorders characterized by pathogenic B-cell activity.
Obinutuzumab is a humanized, glycosylated engineered type II anti-CD20 monoclonal antibody that demonstrates enhanced direct cell death and antibody-dependent cellular cytotoxicity compared to earlier type I anti-CD20 therapeutics. This biosimilar antibody serves as a valuable research tool for investigating B-cell biology, exploring mechanisms of B-cell depletion, studying tumor immunology, and developing novel therapeutic strategies for hematological malignancies and autoimmune diseases.
There are currently no reviews for this product.